Please ensure Javascript is enabled for purposes of website accessibility

Why BioNTech Stock Is Jumping Again Today

By Keith Speights - Mar 31, 2021 at 10:37AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company and its partner Pfizer reported 100% efficacy for their COVID-19 vaccine in kids ages 12 to 15.

What happened

Shares of BioNTech (BNTX 4.94%) were jumping 5.5% at 10:17 a.m. EDT on Wednesday. This marked the second consecutive day of nice gains for the stock. The German biotech reported great fourth-quarter results yesterday. Today's move was due to BioNTech's and Pfizer's (PFE -0.42%) announcement of results from a late-stage study of COVID-19 vaccine BNT162b2 in children ages 12 to 15. 

So what

You couldn't ask for better news from BioNTech's and Pfizer's clinical update. The two companies reported that BNT162b2 demonstrated 100% efficacy along with robust antibody responses in kids ages 12 to 15. This is even higher than the earlier high efficacy levels achieved by the vaccine in older age groups.

BioNTech and Pfizer also stated that BNT162b2 was well tolerated by the children participating in the late-stage study. The companies noted that side effects were "generally consistent with those observed in participants 16 to 25 years of age."

Young boy receiving a shot from a healthcare professional

Image source: Getty Images.

In addition, the partners announced that the first kids ages 6 months through 11 years were dosed last week in a phase 1/2/3 study. A cohort with children ages 5 to 11 has begun dosing, and a cohort of kids from 2 to 5 years old is expected to begin dosing next week.

It's easy to understand why the German biotech stock received a nice boost today. BioNTech and Pfizer could significantly boost sales of BNT162b2 if the vaccine wins Emergency Use Authorization (EUA) for younger age groups.

Now what

BioNTech and Pfizer plan to apply for EUA of BNT162b2 in vaccinating kids ages 12 to 15 within the next few weeks. Pfizer CEO Albert Bourla said that the companies hope to win EUA in the U.S. and other countries quickly, "with the hope of starting to vaccinate this age group before the start of the next school year."

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
$165.96 (4.94%) $7.81
Pfizer Inc. Stock Quote
Pfizer Inc.
$53.77 (-0.42%) $0.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.